Joshua Sabari, MD

@IDEOlogyHealth Permitting NGS results do not identify oncogenic drivers or co-mutations that would favor alternative approaches (i.e., non IO, TKI instead).

@IDEOlogyHealth Or not

@IDEOlogyHealth Or a CR

IDEO Xchange: In resectable NSCLC, which clinical factors most often lead you to use a perioperative chemo‑IO approach rather than neoadjuvant IO/chemo alone?

@NarjustFlorezMD @IDEOlogyHealth I’m learning from you

@JSabari @IDEOlogyHealth He typed something!!!

IDEO Xchange: How would you sequence HER2-directed therapies in a patient with mNSCLC?

@IDEOlogyHealth I agree with @lungoncdoc nuanced discussion, we need to change the discussion from treatment intensification to who should be offer de-escalation because standard of care is now combination therapy

IDEO Xchange: What’s your preferred approach to treatmentintensification for 1L EGFR+ NSCLC?

You are invited to learn about Lung Cancer Treatment Breakthroughs at @Perlmutter_CC @nyulangone Thursday December 11, 2025 6-7PM EST @StermanDaniel, Benjamin Cooper, Harvey Pass, Abraham Chachoua. i.nyulangone.org/vl6

@chulkimMD @LombardiCancer @StephenVLiu Congrats!

Honored to step into the role of Director of Thoracic Oncology. Big shoes to fill following Dr. Liu’s leadership. Grateful for the trust and support - excited to work with this amazing team to provide the best care and drive cutting-edge research @LombardiCancer @StephenVLiu

FDA approval for lung cancer med Hernexeos fiercepharma.com/pharma/boehrin… @Perlmutter_CC @nyulangone @EGFRResisters @Exon20Group

Zongertinib (oral TKI) now @US_FDA approved based off #BeamionLung1 in previously treated metastatic NSCLC w/ HER2+: - 71% ORR w/ 14.1mos mDoR - mPFS 12.4% - ≥Gr 3 AEs in less than 20%. Common AEs includied diarrhea and rash #OncTwitter #MedTwitter

FDA approves zongertinib 120mg po daily for previously treated advanced #HER2 NSCLC. In the phase 1b Beamion-LUNG 1 study @NEJM, RR 71% (42% post ADC), DOR 14.1m, intracranial RR 41%. Main toxicity is diarrhea (56%, 48% grade 1), no ILD. fda.gov/drugs/resource…

#FDA grants accelerated approval to a treatment for non-small cell lung cancer. fda.gov/drugs/resource…

Proud to work here @nyulangone @Perlmutter_CC

Honored to be an Expert Judge Mentor for #EGFRSummit! Submit your abstracts by 8/8 to be part of the next class of @EGFRSummit Young Investigators! ➡️ ce.ceconcepts.com/EGFR2025CFA #EGFR #LCSM #MedTwitter #MedEd

Discussing data hot off the press here at #HawaiiLung25. Dr. Joshua Sabari reviews the latest FDA approval of DatoDXd for our patients with EGFR+ mNSCLC.

@ADesaiMD @lungoncdoc I was trying to blend into the background.

@lungoncdoc I like the attire @JSabari!

Advancements Reshape Treatment for Non-Small Cell Lung Cancer @JSabari @Perlmutter_CC @jainprantesh @RoswellPark #LungCancer curetoday.com/view/advanceme…

📣 HCPs 📣 Do you treat pts w/ rare alterations of #NSCLC? Medical Oncologist Dr @JSabari and Debra Montague (President of @LungCancerEu/founder of @UKALK1) share views on: ➡️The pt pathway ➡️#MedOnc vs Patient needs ➡️The support currently available Watch the video/listen on Spotify/Apple: cor2ed.com/lung-connect/p… 🤝Endorsed by several Patient Advocacy Groups, inc. @WarOnCancer @BrafBombers @Exon20Group @metcrusaders @BiomarkerCo @LungCancerEu & ALK Positive Europe Supported by an Independent Educational Grant from Boehringer Ingelheim #MedEd #NSCLC #PrecisionMedicine 📷